Similarly, CC-115 (31), a dual DNA-PK and mTOR inhibitor, has shown potential in certain cancers, achieving stable disease in CRPC and glioblastoma patients, though it was discontinued in glioblastoma trials due to toxicity and limited efficacy.232–239. The gene discussed is MTOR; the disease is glioblastoma.